EXAS

EXACT Sciences Corporation

EXAS, USA

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

https://www.exactsciences.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EXAS
stock
EXAS

Exact Sciences (NASDAQ:EXAS) Lowered to Hold Rating by Mizuho MarketBeat

Read more →
EXAS
stock
EXAS

Mizuho downgrades Exact Sciences (EXAS) MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$104.5625

Analyst Picks

Strong Buy

17

Buy

6

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

7.69

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.78 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.33 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

22.34 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.36

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 102.53% of the total shares of EXACT Sciences Corporation

1.

FMR Inc

(14.2048%)

since

2025/06/30

2.

Capital World Investors

(9.6134%)

since

2025/06/30

3.

Vanguard Group Inc

(9.4589%)

since

2025/06/30

4.

Wellington Management Company LLP

(6.3405%)

since

2025/06/30

5.

BlackRock Inc

(5.5634%)

since

2025/06/30

6.

American Funds Growth Fund of Amer A

(5.089%)

since

2025/06/30

7.

Capital Group Growth Fnd of Amer Comp

(5.089%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(3.1481%)

since

2025/07/31

9.

Vanguard Health Care Inv

(3.0414%)

since

2025/06/30

10.

State Street Corp

(2.8412%)

since

2025/06/30

11.

Vanguard Small Cap Index

(2.4196%)

since

2025/07/31

12.

T. Rowe Price Associates, Inc.

(1.9561%)

since

2025/06/30

13.

Geode Capital Management, LLC

(1.7098%)

since

2025/06/30

14.

American Funds New Economy A

(1.6251%)

since

2025/06/30

15.

Capital Group New Economy Comp

(1.6251%)

since

2025/06/30

16.

Massachusetts Financial Services Company

(1.5686%)

since

2025/06/30

17.

Mackenzie Investments

(1.5085%)

since

2025/06/30

18.

Vanguard Small Cap Growth Index Inv

(1.3636%)

since

2025/07/31

19.

Champlain Investment Partners, LLC

(1.3363%)

since

2025/06/30

20.

Capital Group Fundamental Invtrs Comp

(1.3169%)

since

2025/06/30

21.

American Funds Fundamental Invs A

(1.3169%)

since

2025/06/30

22.

Fidelity Select Health Care

(1.2941%)

since

2025/07/31

23.

Champlain Mid Cap Fund, LLC

(1.2867%)

since

2025/08/31

24.

Ameriprise Financial Inc

(1.1742%)

since

2025/06/30

25.

Goldman Sachs Group Inc

(1.1696%)

since

2025/06/30

26.

Millennium Management LLC

(1.1629%)

since

2025/06/30

27.

Strategic Advisers Fidelity US TtlStk

(1.1542%)

since

2025/07/31

28.

Holocene Advisors, LP

(1.1331%)

since

2025/06/30

29.

SPDR® S&P Biotech ETF

(1.1133%)

since

2025/08/31

30.

MFS Mid Cap Growth A

(1.0723%)

since

2025/07/31

31.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0712%)

since

2025/07/31

32.

William Blair Investment Management, LLC

(1.0671%)

since

2025/06/30

33.

Dimensional Fund Advisors, Inc.

(1.0298%)

since

2025/06/30

34.

UBS Asset Mgmt Americas Inc

(1.0086%)

since

2025/06/30

35.

BAMCO Inc

(0.9832%)

since

2025/06/30

36.

Fidelity Select Medical Tech and Devcs

(0.9508%)

since

2025/07/31

37.

MFS Mid Cap Growth Equity

(0.946%)

since

2025/06/30

38.

Fidelity Advisor Equity Growth I

(0.9326%)

since

2025/07/31

39.

AQR Capital Management LLC

(0.9261%)

since

2025/06/30

40.

ARK Innovation ETF

(0.9163%)

since

2025/08/28

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.08

Latest Release

Date

2025-09-30

EPS Actual

0.24

EPS Estimate

0.16

EPS Difference

0.08

Surprise Percent

50%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(3.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.